Antonio Guglietta
argenx
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antonio Guglietta as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:58 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04073589 · Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjectsargenx · completed · Healthy Volunteers · study director
- Ph3NCT03669588 · An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weaknessargenx · completed · Generalized Myasthenia Gravis · study director
- Ph2NCT02965573 · A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weaknessargenx · completed · Myasthenia Gravis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:58 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Neurol · 2021651 citationsRCR 46.4
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.J Clin Invest · 2018371 citationsRCR 15.5
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.Neurology · 2019237 citationsRCR 10.9
- 24 citationsRCR 0.6
- Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release.Cardiovasc Ther · 20089 citationsRCR 0.3
- A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.Clin Exp Pharmacol Physiol · 20099 citationsRCR 0.3
- 8 citationsRCR 0.3
- Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers.Fundam Clin Pharmacol · 20097 citationsRCR 0.2
- Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants.Drugs R D · 20243 citationsRCR 0.7